

## Interests Register

Committee – Diagnostics Advisory Committee

Publication Date: February 2022

Topic: EarlyCDT Lung for assessing risk of lung cancer in solid lung nodules

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest Declared	Interest ceased	Comments
Matthew Callister	Specialist Committee Member	Non-financial professional and personal interests	I co-chaired the 2015 British Thoracic Society Pulmonary Nodule Guidelines. The role of biomarkers in discriminating benign from malignant nodules was considered and published evidence regarding EarlyCDT-Lung was reviewed. The GDG commented that “there are no reports evaluating the performance of this test in a cohort of patients with pulmonary nodules” and therefore concluded that its efficacy in discriminating malignant from benign nodules was unknown. The summary evidence statement was “Biomarkers do not offer sufficient accuracy to differentiate malignant from benign nodules” and the recommendation was “Do not use biomarkers in the assessment of pulmonary nodules” Grade D.	2012	Dec 2020	2015	<i>Reviewed at time of application, Chair &amp; AD. Declare and participate</i>
Matthew Callister	Specialist Committee Member	Non-financial professional and personal interests	I am Chief Investigator for the Yorkshire Lung Screening Trial (YLST), and a co-applicant on the YLST Biomarker Study (a nested sub-study within YLST - PI Dr Philip Crosbie, University of Manchester). To date (December 2020) the study collaborated with Everest Diagnostics, a company developing circulating biomarkers of lung cancer. I have no personal connection with the company in question, have received no personal payments and own no shareholdings of other investments in this company.	2019	Dec 2020	2020	<i>Reviewed at time of application, Chair &amp; AD. Declare and participate</i>
Matthew Callister	Specialist Committee Member	Non-financial professional and personal interests	The YLST biomarker company is now planning on being one site for IDx lung. The latter study is run by the University of Southampton, is funded by Innovate UK, and is testing a number of biomarkers in lung screening and nodule evaluation - one of which is Early CDT lung. I am not a listed co-investigator for IDx itself but I will be a co-author on any paper		March 2021		<i>Declare and participate, Chair and AD, March 2021</i>

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest Declared	Interest ceased	Comments
			published looking at the efficacy of these tests. I'm receiving no personal payments for any of these collaborations.				
Matthew Callister	Specialist Committee Member	Non-financial professional and personal interests	The EarlyCDT-Lung test has been proposed as a tool for identifying people at higher risk of lung cancer who might benefit from low-dose CT screening for lung cancer. This is a distinct indication for the test than the one under review here (discrimination of malignant from benign pulmonary nodules once detected). The former indication was the subject of the Early Detection of Lung Cancer in Scotland (ECLS), first presented in abstract form at the World Conference on Lung Cancer 2019 and shortly to be published in the European Respiratory Journal. I was asked to write a blog for the British Thoracic Oncology Group regarding lung cancer screening research presented at WCLC2019 ( <a href="https://www.btog.org/blog/lung-cancer-screening-at-wclc-2019/">https://www.btog.org/blog/lung-cancer-screening-at-wclc-2019/</a> ), and have recently co-authored an editorial for publication in the European Respiratory Journal alongside the main trial paper. Both the blog and subsequent editorial raise some concerns about the design of ECLS and the way in which the performance of the test has been reported by the trial group. The recommendation in both is for further research to be undertaken to determine the role of EarlyCDT in this scenario. As discussed above though, use of EarlyCDT in this way is not the matter under consideration in this review.	2019	Dec 2020	2020	<i>Reviewed at time of application, Chair &amp; AD. Declare and participate</i>
Philip Crosbie	Specialist committee member	Financial	Everest Detection: biotechnology startup company - consultancy fees and share options for lung cancer early detection and screening. The company collaborate with the Yorkshire Lung Screening Trial biomarker study which I lead. Everest Detection do not currently have a product.	2018	Dec 2020	ongoing	<i>Reviewed at time of application, Chair &amp; AD. Declare and participate</i>

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest Declared	Interest ceased	Comments
Philip Crosbie	Specialist committee Member	Financial	Novartis: honoraria – lung cancer survey design	2020	Dec 2020	2020	<i>Reviewed at time of application, Chair &amp; AD. Declare and participate</i>
Philip Crosbie	Specialist committee Member	Financial	AstraZeneca: honoraria – lung cancer screening talk and round table discussion	2020	Dec 2020	2020	<i>Reviewed at time of application, Chair &amp; AD. Declare and participate</i>
Philip Crosbie	Specialist committee Member	Non-financial personal and professional interests	Contributed to NICE Medtech Innovation Briefing related to EarlyCDT-Lung	Dec 2019	Dec 2020	Jan 2020	<i>Reviewed at time of application, Chair &amp; AD. Declare and participate</i>
Philip Crosbie	Specialist committee Member	Non-financial professional and personal interests	Chief investigator Yorkshire Lung Screening Trial Biomarker study (assess EarlyCDT-Lung in lung screening cohort).	March 2021	Dec 2020		<i>Reviewed at time of application, Chair &amp; AD. Declare and participate</i>
Jesme Fox	Lay Specialist committee member	Financial	<p>As with many registered charities, my employer, Roy Castle Lung Cancer Foundation (RCLCF) has received grants/donations from multiple pharmaceutical and commercial businesses. These have been for specified projects (eg, conference organisation, patient information leaflets, Global Lung Cancer Coalition etc.) and not core funding. On a personal perspective, I have presented at many conferences and participated in advisory boards, organised by multiple pharmaceutical companies. Over the past year, I have participated in virtual Advisory Boards for Boehringer Ingelheim, BMS, AstraZeneca, Novartis, Debiopharma and Takeda (see dates below). In lieu of my time, donations have been given by the company to RCLCF. At no time have I personally accepted an honorarium.</p> <p>Boehringer Ingelheim Advisory 26/02/21 BMS Advisory 09/12/20, 02/02/21, 12/03/21, 17/07/21, 22/07/21. AstraZeneca Advisory 12/03/21 Takeda Advisory 28/06/21 Novartis Advisory 10/12/20 Debiopharma 22/06/21, 07/09/21</p>		August 2021		<i>Reviewed at time of application, Chair &amp; AD. Declare and participate</i>

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest Declared	Interest ceased	Comments
Jesme Fox	Lay Specialist committee member	Non-financial professional and personal interests	Medical Director, Roy Castle Lung Cancer Foundation	1998	August 2021	Ongoing	<i>Reviewed at time of application, Chair &amp; AD. Declare and participate</i>
Jesme Fox	Lay Specialist committee member	Non-financial professional and personal interests	Branch President, Northwest Somerset Branch of Parkinson's UK	2014	August 2021	Ongoing	<i>Reviewed at time of application, Chair &amp; AD. Declare and participate</i>
Jesme Fox	Lay Specialist committee member	Non-financial professional and personal interests	Secretary, Global Lung Cancer Coalition	2005	August 2021	Ongoing	<i>Reviewed at time of application, Chair &amp; AD. Declare and participate</i>
Jesme Fox	Lay Specialist committee member	Non-financial professional and personal interests	Member, British Thoracic Oncology Group	2012	August 2021	Ongoing	<i>Reviewed at time of application, Chair &amp; AD. Declare and participate</i>
Jesme Fox	Lay Specialist committee member	Non-financial professional and personal interests	Member of International Association for the Study of Lung Cancer	2011	August 2021	Ongoing	<i>Reviewed at time of application, Chair &amp; AD. Declare and participate</i>
Jesme Fox	Lay Specialist committee member	Non-financial professional and personal interests	Member, Lung Cancer and Mesothelioma Clinical Expert Group	2019	August 2021	Ongoing	<i>Reviewed at time of application, Chair &amp; AD. Declare and participate</i>
Jesme Fox	Lay Specialist committee member	Non-financial professional and personal interests	Member of the NHSE&I Early Detection 'Task and Finish Group'	2018	August 2021	Ongoing	<i>Reviewed at time of application, Chair &amp; AD. Declare and participate</i>
Jesme Fox	Lay Specialist committee member	Non-financial professional and personal interests	Member of the NHSE&I Lung Cancer Screening Advisory Group	2019	August 2021	Ongoing	<i>Reviewed at time of application, Chair &amp; AD. Declare and participate</i>
Jesme Fox	Lay Specialist committee member	Indirect interests	Roy Castle Lung Cancer Foundation is a registered charity, with an interest in ensuring equitable access to best practice diagnostics, treatment and care for all lung cancer patients	1998	August 2021	Ongoing	<i>Reviewed at time of application, Chair &amp; AD. Declare and participate</i>
Jesme Fox	Lay Specialist committee member	Indirect interests	I represent the Global Lung Cancer Coalition on the Board of the Lung Ambition Alliance (the LAA currently receives funding from Astra Zeneca and Guardant Health)	2017	August 2021	Ongoing	<i>Reviewed at time of application, Chair &amp; AD. Declare and participate</i>
Jesme Fox	Lay Specialist committee member	Indirect interests	I represent the Global Lung Cancer Coalition on the Global Cancer Coalition Network	2020	August 2021	Ongoing	<i>Reviewed at time of application, Chair &amp; AD. Declare and participate</i>
Seamus Grundy	Specialist Committee Member	Financial	Clinical Expert Reviewer for British Standards Institute. I provide expert opinion to the British Standards Institute for Respiratory Devices. I have not provided any opinion directly or indirectly related to the technology under review by this committee	2015	Dec 2020		<i>Reviewed at time of application, Chair &amp; AD. Declare and participate</i>

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest Declared	Interest ceased	Comments
Seamus Grundy	Specialist Committee Member	Non-financial professional and personal interests	Salford Lung Health Check Biomarker Study: I am Chief Investigator for this study. I am collaborating with Everest Detection Ltd. The research relates to developing biomarkers to improve the early detection of lung cancer within lung cancer screening programs using blood and other biological samples such as urine or saliva.	August 2019	Dec 2020	July 2021	<i>Reviewed at time of application, Chair &amp; AD. Declare and participate</i>
Seamus Grundy	Specialist Committee Member	Non-financial professional and personal interests	NHSI grant application in collaboration with QURE: Grant application for NHS Innovation awards to evaluate the impact of regional roll out of AI reporting of Chest x-rays on diagnostic capacity and efficiency.	September 2021	03/11/2021		<i>Declare and participate, Chair and AD 5 Nov 2021</i>
Helen Johnstone	Specialist Committee Member	None	-	-	-	-	-
Eric Lim	Specialist Committee Member	Financial interests	Abbott Molecular - consultancy. Payment to EL, project specific, not salaried position	2019	Feb 2021	2020	<i>Declare and participate, Chair &amp; AD, May 2021</i>
Eric Lim	Specialist Committee Member	Financial interests	Glaxo Smith Kline - consultancy	2014	Feb 2021	2015	<i>Declare and participate, Chair &amp; AD, May 2021</i>
Eric Lim	Specialist Committee Member	Financial interests	Pfizer - consultancy and educational presentations	2018	Feb 2021	2019	<i>Declare and participate, Chair &amp; AD, May 2021</i>
Eric Lim	Specialist Committee Member	Financial interests	Norvatis - consultancy	2016	Feb 2021	2017	<i>Declare and participate, Chair &amp; AD, May 2021</i>
Eric Lim	Specialist Committee Member	Financial interests	Medtronic - travel, consultancy – payment to EL, project specific, not salaried position. Travel in line with public sector (economy class).	2016	Feb 2021		<i>Declare and participate, Chair &amp; AD, May 2021</i>
Eric Lim	Specialist Committee Member	Financial interests	Roche - educational presentations, advisory board – payment to EL, project specific, not salaried position	2019	Feb 2021		<i>Declare and participate, Chair &amp; AD, May 2021</i>
Eric Lim	Specialist Committee Member	Financial interests	Lily - educational presentations	2016	Feb 2021	2017	<i>Declare and participate, Chair &amp; AD, May 2021</i>
Eric Lim	Specialist Committee Member	Financial interests	Boehringer Ingelheim - educational presentations	2018	Feb 2021	2019	<i>Declare and participate, Chair &amp; AD, May 2021</i>

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest Declared	Interest ceased	Comments
Eric Lim	Specialist Committee Member	Financial interests	Medela - travel, accommodation, educational presentation – payment to EL, project specific, not salaried position; travel and accommodation in line with public sector. Research funds to EL's institution	2016	Feb 2021		<i>Declare and participate, Chair &amp; AD, May 2021</i>
Eric Lim	Specialist Committee Member	Financial interests	ScreenCell - research funds to EL's institution	2016	Feb 2021	2018	<i>Declare and participate, Chair &amp; AD, May 2021</i>
Eric Lim	Specialist Committee Member	Financial interests	Johnson and Johnson	2016	Feb 2021		<i>Declare and participate, Chair &amp; AD, May 2021</i>
Eric Lim	Specialist Committee Member	Financial interests	Clearbridge Biomedics - research funds to EL's institution	2016	Feb 2021	2018	<i>Declare and participate, Chair &amp; AD, May 2021</i>
Eric Lim	Specialist Committee Member	Financial interests	Illumina - supplied sequencing services	2016	Feb 2021	2017	<i>Declare and participate, Chair &amp; AD, May 2021</i>
Eric Lim	Specialist Committee Member	Financial interests	Guardant Health - research funds to EL's institution	2017	Feb 2021		<i>Declare and participate, Chair &amp; AD, May 2021</i>
Eric Lim	Specialist Committee Member	Financial interests	AstraZeneca - educational presentations, advisory board - payment to EL, project specific, not salaried position	2019	Feb 2021		<i>Declare and participate, Chair &amp; AD, May 2021</i>
Eric Lim	Specialist Committee Member	Financial interests	Bristol Meyers Squib - educational presentations, - payment to EL, project specific, not salaried position	2019	Feb 2021	2020	<i>Declare and participate, Chair &amp; AD, May 2021</i>
Eric Lim	Specialist Committee Member	Non-financial professional and personal interests	Planning a research project (PhD) on use of earlyCDT for the evaluation of ground glass opacities		Feb 2021		<i>Reviewed at time of application, Chair &amp; AD. Declare and participate</i>
Eric Lim	Specialist Committee Member	Non-financial professional and personal interests	Planning a RCT on the utility of blood based diagnosis for early surgical management		Feb 2021		<i>Reviewed at time of application, Chair &amp; AD. Declare and participate</i>
Emma O'Dowd	Specialist Committee Member	Non-financial professional and personal interests	Co-author on research looking at the role of artificial intelligence in pulmonary nodule risk stratification and co-author on editorials relating to nodules in lung cancer screening but these are not specifically related to the	Jan 2020	Dec 2020	April 2020	<i>Reviewed at time of application, Chair &amp; AD. Declare and participate</i>

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest Declared	Interest ceased	Comments
			matter under review and there is no ongoing research related to this/ I do not have any affiliations related to this research.				
Janette Rawlinson	Lay Specialist Committee Member	Financial	Lay member of Sandwell & West Birmingham Clinical Commissioning Group (paid for governance role via payroll/ contract for services not employment — 5-7 days per month). I am a member of the SWB Cancer steering group and contributed to producing a video for HCPs to raise awareness of CXR/earlier detection of LC –West Midlands has no screening pilot projects within the NHSE initial programme although NHSE innovation funding given to Stoke and Coventry & Warwickshire Trust will be included in future. The CCG where I am a lay director does not commission services from either Trust nor any cancer related services (commissioned by NHSE Specialised services)	April 2013	Dec 2020	March 2021	<i>Reviewed at time of application, Chair &amp; AD. Declare and participate</i>
Janette Rawlinson	Lay Specialist Committee Member	Non-financial professional and personal interests	NHSE Lung screening advisory group – patient rep – group restructured mid 2020. I have been a patient rep on this and its predecessor to be independent, impartial and contribute on behalf of patients/carers/public to issues affecting people affected by screening and discuss progress, challenges and potential solutions. The committee has no role in pilot project evaluation - contracted separately. It has moved from a concept of promoting lung healthchecks to wide extension of pilot schemes across England pre and post publication of NELSON trial results. It brings together expertise from some of those dealing directly with early detection of pulmonary nodules, their incidence and the different ways that parts of the country/system deal with incidental findings during health checks, discussing quality standards and protocols and fit within the NOLCP in a bid to improving LC outcomes.	March 2017	Dec 2020	Ongoing	<i>Reviewed at time of application, Chair &amp; AD. Declare and participate</i>

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest Declared	Interest ceased	Comments
Janette Rawlinson	Lay Specialist Committee Member	Non-financial professional and personal interests	NHSE lung cancer Clinical Expert Group – patient rep - produced guidance on managing pulmonary nodules including patient information in Apr 2017 and contributed to patient information for national lung screening pilot projects – contribute to amendments in policy/process re LC (especially during pandemic) from a patient /public perspective	Mar 2017	Dec 2020	Ongoing	<i>Reviewed at time of application, Chair &amp; AD. Declare and participate</i>
Janette Rawlinson	Lay Specialist Committee Member	Non-financial professional and personal interests	Roy Castle lung cancer foundation – member of patient literature panel – regularly contribute to patient information updates relating to lung cancer, treatment and living with lung cancer, attended several events including APPG roundtable house of Lords Feb 2017 about targeted LC treatments and need for earlier diagnosis. RCLCF previously provided secretariat support for lung screening advisory group - now undertaken by NHSE	2011	Dec 2020	Ongoing	<i>Reviewed at time of application, Chair &amp; AD. Declare and participate</i>
Janette Rawlinson	Lay Specialist Committee Member	Non-financial professional and personal interests	Article published in BMJ Oct 2020 – co – author on pulmonary nodules <a href="https://www.bmj.com/content/371/bmj.m3673.full?ijkey=C6mMQiTaAM3DD4S&amp;keytype=ref">https://www.bmj.com/content/371/bmj.m3673.full?ijkey=C6mMQiTaAM3DD4S&amp;keytype=ref</a>	October 2020	Dec 2020	Ongoing	<i>Reviewed at time of application, Chair &amp; AD. Declare and participate</i>
Janette Rawlinson	Lay Specialist Committee Member	Non-financial professional and personal interests	NCRI advanced disease lung group – contribute to reviews of LC trials portfolio, early design studies (Dragons' Den type events), annual trials day and annual report (3 meetings per annum) and Never Smokers lung cancer workstream	Dec 2018	Dec 2020	Ongoing	<i>Reviewed at time of application, Chair &amp; AD. Declare and participate</i>
Janette Rawlinson	Lay Specialist Committee Member	Non-financial professional and personal interests	British Thoracic Oncology Group (BTOG) steering committee member – advocate – representing patient/carers in charity responsible for education on all thoracic malignancies – increased its online educational presence throughout pandemic to improve awareness of all aspects of lung cancer	May 2017	October 2021	Ongoing	<i>Declare and participate, Chair and AD 8 Nov 2021</i>
Janette Rawlinson	Lay Specialist Committee Member	Non-financial professional and personal interests	ERS/ELF patient advisory group on lung cancer and lung screening – attended several consultative events including Barcelona 2018 and commented from patient perspective on European paper on lung screening (from Apr 2018 – published Feb 2020)	2015	Dec 2020	Ongoing	<i>Reviewed at time of application, Chair &amp; AD. Declare and participate</i>



Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest Declared	Interest ceased	Comments
			<a href="https://link.springer.com/article/10.1007/s00330-020-06727-7">https://link.springer.com/article/10.1007/s00330-020-06727-7</a> . Spoke on LC patient perspectives at Presidential summit, Athens 2018 resulting in this LC screening film <a href="https://www.ersvision.org/videos/lung-cancer-screening?utm_source=ERS+newsletter&amp;utm_campaign=48ef922725-ers_vision_public_health_2nd_sendout_COPY_01&amp;utm_medium=email&amp;utm_term=0_372fc3467c-48ef922725-62765321">https://www.ersvision.org/videos/lung-cancer-screening?utm_source=ERS+newsletter&amp;utm_campaign=48ef922725-ers_vision_public_health_2nd_sendout_COPY_01&amp;utm_medium=email&amp;utm_term=0_372fc3467c-48ef922725-62765321</a>				
Janette Rawlinson	Lay Specialist Committee Member	Non-financial professional and personal interests	NCRAS Clinical reference group member of RICCR working group (review of informed consent cancer registry) - contribute patient perspective (quarterly) –helped inform my knowledge about consent issues for consideration in lung or other screening – participated in all national cancer screening programmes in recent years so received various information/consent literature to compare	Mar 2019	Dec 2020	Ongoing	<i>Reviewed at time of application, Chair &amp; AD. Declare and participate</i>
Janette Rawlinson	Lay Specialist Committee Member	Non-financial professional and personal interests	West Midlands Cancer Alliance – lung cancer & mesothelioma expert advisory group patient representative contribute patient/carer perspective on LC issues (2 p.a) - Stoke lung screening project had started prior to pandemic but paused and C&W started recently –not directly involved in either. Sandwell & WB and BSOL pilots just announced	June 2017	Dec 2020	Ongoing	<i>Reviewed at time of application, Chair &amp; AD. Declare and participate</i>
Janette Rawlinson	Lay Specialist Committee Member	Non-financial professional and personal interests	CRUK Stratified Medicine Programme board member patient representative – adding patient/carer perspective for, consideration of additional arms/treatments/changed gene panels, concerns, etc and as trial approaches its end review potential publication and dissemination routes(2 p.a)	Jan 2015	Dec 2020	Ongoing	<i>Reviewed at time of application, Chair &amp; AD. Declare and participate</i>
Janette Rawlinson	Lay Specialist Committee Member	Non-financial professional and personal interests	CRUK Patient rep panel member for CERP – assess funding bids, review trials' progress, review CTU impact of Covid 19 (twice a year)	Sept 2018	Dec 2020	Ongoing	<i>Reviewed at time of application, Chair &amp; AD. Declare and participate</i>

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest Declared	Interest ceased	Comments
Janette Rawlinson	Lay Specialist Committee Member	Non-financial professional and personal interests	EORTC Patient Panel – speaker at EORTC survivorship summit (Feb 2018) about issues facing people following cancer diagnosis – since then joined EORTC Patient panel (meet annually – virtually since pandemic)	Apr 2019	Dec 2020	Ongoing	<i>Reviewed at time of application, Chair &amp; AD. Declare and participate</i>
Janette Rawlinson	Lay Specialist Committee Member	Non-financial professional and personal interests	NHSE Specialist commissioning services specialist cancer surgery – appointed as Patient Public voice partner to clinical reference group - not yet met	Sept 2021	October 2021	Ongoing	<i>Declare and participate, Chair and AD 8 Nov 2021</i>
Janette Rawlinson	Lay Specialist Committee Member	Financial	Optellum study – PPI collaborator – study to determine the impact of AI for LC nodule risk stratification on service intervention, health economics and patient outcomes– working with PPI lead on optimum way to engage participants for workshop to assess people's acceptability/understanding of machine learning for reading pulmonary images – project still in set-up – workshop planned for Nov 2021. Honorarium received for the first piece of work in line with INVOLVE rates.	May 2021	October 2021	Ongoing	<i>Declare and participate, Chair and AD 8 Nov 2021</i>
Janette Rawlinson	Lay Specialist Committee Member	Non-financial professional and personal interests	Co-author on paper on selecting eligible participants for lung cancer screening <a href="https://thorax.bmj.com/content/early/2021/10/28/thoraxjnl-2021-217142">https://thorax.bmj.com/content/early/2021/10/28/thoraxjnl-2021-217142</a>	Oct 2021	October 2021	Ongoing	<i>Declare and participate, Chair and AD 8 Nov 2021</i>
James Wilson	Specialist Committee Member	Financial	Private practice	August 2018	Dec 2020	Ongoing	<i>Reviewed at time of application, Chair &amp; AD. Declare and participate</i>